


Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

Graphical abstract



Authors

Marcos F. Fondevila, Uxia Fernandez, Violeta Heras, ..., Maria L. Martinez-Chantar, Robert F. Schwabe, Ruben Nogueiras

Correspondence

marcos.fernandez.fondevila@gmail.com (M.F. Fondevila), ruben.nogueiras@usc.es (R. Nogueiras).

Lay summary

We show that the enzyme carnitine palmitoyltransferase 1A (CPT1A) is elevated in hepatic stellate cells (HSCs) in patients with fibrosis and mouse models of fibrosis, and that CPT1A induces the activation of these cells. Inhibition of CPT1A ameliorates fibrosis by preventing the activation of HSCs.

Highlights

- CPT1A is overexpressed in HSCs from patients with fibrosis and positively correlates with fibrosis and NAFLD activity score.
- Fatty acid oxidation is increased in activated HSCs and CPT1A inhibition blunts HSC activation by reducing mitochondrial activity.
- In experimental models, CPT1A-induced fibrogenesis is dependent on ATP availability.
- The specific deletion of CPT1A in mouse HSCs protects against fibrosis.



Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

Marcos F. Fondevila^{1,2,*}, Uxia Fernandez^{1,2,†}, Violeta Heras^{1,†}, Tamara Parracho¹, Maria J. Gonzalez-Rellan¹, Eva Novoa¹, Begoña Porteiro¹, Cristina Alonso³, Rebeca Mayo³, Natalia da Silva Lima¹, Cristina Iglesias¹, Aveline A. Filliol⁴, Ana Senra¹, Teresa C. Delgado^{5,6}, Ashwin Woodhoo⁷, Laura Herrero^{2,8}, Dolors Serra^{2,8}, Vincent Prevot⁹, Markus Schwaninger¹⁰, Miguel López^{1,2}, Carlos Dieguez^{1,2}, Oscar Millet^{3,5}, Jose M. Mato^{3,5}, Francisco J. Cubero^{11,12}, Marta Varela-Rey⁷, Paula Iruzubieta¹³, Javier Crespo¹³, Maria L. Martinez-Chantar^{5,6}, Robert F. Schwabe⁴, Ruben Nogueiras^{1,2,14,*}

¹Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain; ²CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain; ³OWL Metabolomics, Technology Park of Bizkaia, Derio, Bizkaia, Spain; ⁴Department of Medicine, Columbia University, New York, NY, USA; ⁵Liver Disease Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain; ⁶CIBER Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; ⁷Gene Regulatory Control in Disease, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain; ⁸Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain; ⁹Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S 1172, European Genomic Institute for Diabetes (EGID), F-59000 Lille, France; ¹⁰University of Lübeck, Institute for Experimental and Clinical Pharmacology and Toxicology, Lübeck, Germany; ¹¹Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine, 28040 Madrid, Spain; ¹²Health Research Institute Gregorio Marañón (IiSGM), 28007 Madrid, Spain; ¹³Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital. Clinical and Translational Digestive Research Group, IDIVAL, Santander, Spain; ¹⁴Galician Agency of Innovation (GAIN), Xunta de Galicia, Santiago de Compostela, Spain

Background & Aims: The pathogenesis of liver fibrosis requires activation of hepatic stellate cells (HSCs); once activated, HSCs lose intracellular fatty acids but the role of fatty acid oxidation and carnitine palmitoyltransferase 1A (CPT1A) in this process remains largely unexplored.

Methods: CPT1A was found in HSCs of patients with fibrosis. Pharmacological and genetic manipulation of CPT1A were performed in human HSC cell lines and primary HSCs. Finally, we induced fibrosis in mice lacking CPT1A specifically in HSCs.

Results: Herein, we show that CPT1A expression is elevated in HSCs of patients with non-alcoholic steatohepatitis, showing a positive correlation with the fibrosis score. This was corroborated in rodents with fibrosis, as well as in primary human HSCs and LX-2 cells activated by transforming growth factor β 1 (TGF β 1) and fetal bovine serum (FBS). Furthermore, both pharmacological and genetic silencing of CPT1A prevent TGF β 1- and FBS-induced HSC activation by reducing mitochondrial activity. The overexpression of CPT1A, induced by saturated fatty acids and reactive oxygen species, triggers mitochondrial activity and

the expression of fibrogenic markers. Finally, mice lacking CPT1A specifically in HSCs are protected against fibrosis induced by a choline-deficient high-fat diet, a methionine- and choline-deficient diet, or treatment with carbon tetrachloride.

Conclusions: These results indicate that CPT1A plays a critical role in the activation of HSCs and is implicated in the development of liver fibrosis, making it a potentially actionable target for fibrosis treatment.

Lay summary: We show that the enzyme carnitine palmitoyltransferase 1A (CPT1A) is elevated in hepatic stellate cells (HSCs) in patients with fibrosis and mouse models of fibrosis, and that CPT1A induces the activation of these cells. Inhibition of CPT1A ameliorates fibrosis by preventing the activation of HSCs.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

One of the most common types of fibrotic liver occurs in patients with non-alcoholic fatty liver disease (NAFLD), which may develop into non-alcoholic steatohepatitis (NASH). Hepatic stellate cells (HSCs) are the primary fibrogenic cell type activated following liver injury, moving from a quiescent phenotype rich in vitamin A into activated myofibroblast-like cells with proliferative and migratory properties.¹⁻³

In NAFLD, hepatocytes ectopically store fatty acids as a consequence of excessive free fatty acids when the capacity to store lipids safely is exceeded. In contrast, activation of HSCs

Keywords: CPT1A; NASH; fibrosis; metabolism; fatty acids; beta oxidation.

Received 27 September 2021; received in revised form 2 February 2022; accepted 3 February 2022; available online 12 February 2022

* Corresponding author. Address: Department of Physiology, Research Centre of Molecular Medicine and Chronic Diseases (CIMUS), Instituto de Investigación Sanitaria de Santiago de Compostela, Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain.

E-mail addresses: marcos.fernandez.fondevila@gmail.com (M.F. Fondevila), ruben.nogueiras@usc.es (R. Nogueiras).

† UF and VH contributed equally
<https://doi.org/10.1016/j.jhep.2022.02.003>



ELSEVIER

leads to a loss of fatty acid content.^{4,5} This event has been mainly explained by the reduction in the expression of adipogenic transcription factors, which are abundant in quiescent HSCs, during the transdifferentiation of these cells.^{6,7} Accordingly, activation of HSCs is inhibited by peroxisome proliferator-activated receptor (PPAR) γ signaling, in part due to reduced WNT activity.⁸

Proliferation and migration of HSCs require considerable energy, triggering a cellular metabolic rewiring.⁹ For instance, HSC activation relies on the stimulation of glycolysis,¹⁰ glutaminolysis,¹¹ and *de novo* lipogenesis.¹² However, the potential role of fatty acid oxidation (FAO) in the decline of lipid droplets in activated HSCs remains largely unknown. Carnitine palmitoyltransferase 1A (CPT1A) is a mitochondrial enzyme that is the rate-limiting step in the beta oxidation of medium- and long-chain fatty acids which generates energy in the form of ATP. The vast majority of research on CPT1A has used mouse models that are deficient for this enzyme in all liver cell types or only in hepatocytes. Notably, these results show that increasing the activity of CPT1A reduces diet-induced hepatic triglyceride levels.^{13–15} Indeed, lipid accumulation in hepatocytes induces fibrogenic activation of HSCs. Despite the loss of fatty acids upon HSC activation, however, the potential role of CPT1A in these specific cells has not been studied.

In the present study, we investigated the function of CPT1A within HSCs during liver fibrosis using *in vivo* mouse models and *in vitro* cell models.

Materials and methods

Human samples

The study population included 21 patients with biopsy-proven NASH, at different stages of fibrosis progression, who underwent a liver biopsy during bariatric surgery or with a diagnostic purpose at the Marqués de Valdecilla University Hospital (Santander, Spain) (Table S1). Liver samples from histologically normal livers (without steatosis) were obtained from 6 individuals during programmed cholecystectomy – these were selected as healthy controls. Patients consumed <20 g alcohol/day, did not take potentially hepatotoxic drugs, had no analytical evidence of iron overload, and were seronegative for autoantibodies and for hepatitis B/C viruses and human immunodeficiency virus. Hepatic histopathological analysis was performed according to the scoring system of Kleiner *et al.*¹⁶ Minimal criteria for NASH included the combined presence of grade 1 steatosis, hepatocellular ballooning, and lobular inflammation with or without fibrosis. This study was performed in agreement with the Declaration of Helsinki and with local and national laws. The Human Ethics Committee of the hospital approved the study procedures, and all participants voluntarily signed an informed written consent before inclusion in the study. Correlation analysis between amount of CPT1A in α -smooth muscle actin (α SMA)-positive cells and different variables of these patients are included in Table S2.

Animals and diets

Eight-week-old male C57 BL/6J mice were kept under a 12 hour light/dark cycle and had *ad libitum* access to standard diet, methionine-choline-deficient diet (MCDD) (A02082002BR, Research Diets), high-fat diet (HFD) (D12492 60% fat, Research Diets), or choline-deficient and high-fat diet (CDHFD) (D05010402; 45% fat, Research Diets) for the specified times.

Food intake and body weight were monitored weekly during the experimental phase in all the experiments. Animal protocols were approved by the Committee at the University of Santiago de Compostela (15010/14/007).

Results

CPT1A is upregulated in activated HSCs from patients and rodents with fibrosis

Immunofluorescence labeling in liver sections of healthy individuals or patients with fibrotic NASH showed that CPT1A colocalized with α SMA in fibrotic liver but not in healthy liver (Fig. 1A and Fig. S1). Furthermore, the area of colocalization positively correlated with the fibrosis score and the NAFLD activity score (Fig. 1A). Correlation of CPT1A- α SMA area with other variables is available in Table S2. To investigate the expression of CPT1A independent of HSCs' activation status, we also analyzed correlations with glial fibrillary acidic protein (GFAP) a marker of quiescent HSCs.^{2,17,18} The colocalization of CPT1A with GFAP was scarce (Fig. S2). Moreover, the merged CPT1A/GFAP staining did not correlate with fibrosis score (Fig. S2B-C). These findings indicate that the majority of CPT1A is expressed in activated HSCs and proportionally to fibrosis score, while its levels in quiescent HSCs are comparatively very low.

We next investigated the immunofluorescence of CPT1A in livers from mouse models of diet-induced fibrosis. Mice were fed a HFD with 45% kcal fat content or a CDHFD for 52 weeks. In these mouse models of fibrosis, we detected a clear colocalization of CPT1A and α SMA, which was significantly higher than in control mice fed a standard diet (SD) (Fig. 1B, Fig. S3A). We also used a carbon tetrachloride-induced fibrosis model: increased colocalization of CPT1A and α SMA staining was observed in carbon tetrachloride-treated mice compared to non-treated control mice (Fig. S3B).

In corroboration with the histological data, we found that the levels of CPT1A (both at the protein and the mRNA levels), as well as of collagen alpha 1 (COL1 α 1) and collagen alpha 2 (COL1 α 2), were augmented in whole liver and in isolated hepatocytes (Fig. S3C) and isolated HSCs (Fig. 2A) from mice fed a CDHFD for 52 weeks. Similar results were observed for mice treated with carbon tetrachloride or fed a MCDD: these mice displayed augmented levels of CPT1A in the liver as well as in isolated HSCs (Fig. 2B-C, Fig. S3D-E). While CPT1A expression was higher in isolated hepatocytes from mice fed a MCDD, it was decreased in mice treated with carbon tetrachloride (Fig. S3D-E). We next evaluated the potential alteration of CPT1A expression during the activation of primary human HSCs (phHSCs). Notably, treatment with transforming growth factor- β 1 (TGF β 1) – a potent fibrogenic inducer – increased the expression of CPT1A as well as of the pro-fibrotic markers α SMA, COL1 α 1, and COL1 α 2 (Fig. 2D-E). Overall, these results indicated that CPT1A expression is consistently elevated in activated HSCs in both humans and rodents.

Inhibition of CPT1A blocks *in vitro* HSC activation

Because CPT1A is upregulated upon HSC activation, we hypothesized that inhibiting CPT1A could reduce HSC activation by decreasing mitochondrial activity and FAO. As expected, a 24 hour TGF β 1 treatment in phHSCs increased the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) indicative of glycolytic flux (Fig. 3A). Strikingly, treatment with etomoxir, a small molecule irreversible inhibitor of CPT1A,




Fig. 1. CPT1A is upregulated in activated HSCs of fibrotic livers. (A) Representative colocalized immunofluorescence for α SMA (red), expressed in the cytoplasm of activated HSCs, with CPT1A (green) in healthy individuals ($n = 6$) and patients with NASH and fibrosis ($n = 21$). Nuclei were stained with DAPI (blue). Correlation of α SMA-CPT1A merged area with the fibrosis score and NAFLD activity score is shown (Spearman correlation). (B) Representative colocalized immunofluorescence for α SMA with CPT1A in liver sections from mice fed a SD, a HFD or a CDHFD for 52 weeks ($n = 4$). CDHFD, choline-deficient and high-fat diet; HFD, high-fat diet; HSCs, hepatic stellate cells; NAFLD, non-alcoholic fatty liver disease; SD, standard diet.

completely blocked TGF β 1-induced OCR without affecting ECAR (Fig. 3A). Quantification of the different parameters of mitochondrial function revealed that etomoxir blunted TGF β 1-

induced basal respiration, ATP-linked respiration, and maximal respiration (Fig. 3B). Furthermore, TGF β 1-induced expression of fibrotic markers was abolished by etomoxir (Fig. 3C). Similar to




Fig. 2. CPT1A is upregulated in activated primary cultures of HSCs from mice or human patients. (A–C) Mice were i) fed a CDHFD or (as a control) a SD for 52 weeks (A), ii) fed a SD and treated with carbon tetrachloride (0.6 ml/kg i.p.) or (as a control) with vehicle once a week for 6 weeks (B), or iii) fed a MCDD or a SD for 4 weeks (C). Representative microphotographs are shown of H&E (upper panel) and Sirius red (lower panel) staining of liver sections. Expression of COL1α1, COL1α2, and CPT1A in isolated HSCs is shown (n = 3 or 4). (D) phHSCs from a donor were treated with 8 ng/ml TGFβ1 for 24 h (n = 8). Expression of fibrotic markers and CPT1A is shown. (E) Correlation between CPT1A expression and αSMA, COL1α1, and COL1α2 (Spearman correlation). HPRT was used to normalize mRNA levels. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 according to a Student's *t* test. CDHFD, choline-deficient and high-fat diet; HSCs, hepatic stellate cells; MCDD, methionine-choline-deficient diet; phHSCs, primary human HSCs; SD, standard diet.




Fig. 3. Either pharmacological or genetic inhibition of CPT1A attenuates the metabolic and fibrogenic activation induced by TGFβ1 in pHSCs. (A) OCR and ECAR in pHSCs treated with TGFβ1 and 4 μM etomoxir for 24 h (n = 4). Arrows indicate the timepoint at which mitochondrial respiration modulators (Oligo, FCCP, or Rot/AA) were added to the assay. Right, graph depicting the effect of TGFβ1 or etomoxir treatments on quiescent or energetic metabolic states, based on quantification of glycolysis and OCR during basal metabolism. (B) Parameters of mitochondrial function (n = 4). (C) Expression of fibrotic markers (n = 4). (D) Expression of CPT1A in pHSCs with CPT1A silencing and 24 h TGFβ1 treatment (n = 4). (E) OCR, ECAR, and basal metabolism in pHSCs with CPT1A silencing and 24 h TGFβ1 treatment (n = 4). (F) Parameters of mitochondrial function (n = 4). (G) Expression of fibrotic markers (n = 4). mRNA levels were normalized to the housekeeping gene HPRT. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 according to a one-way ANOVA followed by Bonferroni *post hoc* multiple comparison test. ECAR, extracellular acidification rate; FCCP, phenylhydrazone; OCR, oxygen consumption rate; Oligo, oligomycin; pHSCs, primary human hepatic stellate cells; Rot/AA, rotenone/antimycin A; si, small-interfering RNA.

pharmacological inhibition, genetic silencing of CPT1A in pHSCs also blocked the TGFβ1-induced increase in OCR and decreased the expression of fibrotic markers (Fig. 3D-G).

We next tested our conditions using LX-2 cells, a human HSC cell line that has been extensively characterized and retains key features of hepatic stellate signaling.¹⁹ In an initial time-response experiment with TGFβ1, we found that as soon as 1 hour after initiation of TGFβ1, mRNA expression of CPT1A, but not of CPT2, was significantly increased and remained at high levels at the 6 hour and 12 hour timepoints of treatment (Fig. S4A). This upregulation occurred before any detectable upregulation of COL1α1

and COL1α2 (Fig. S4B). Moreover, treatment with platelet-derived growth factor, another potent activator of HSCs, effectively increased the expression of proliferation markers, without altering CPT1A expression levels (Fig. S4C). LX-2 cells treated with TGFβ1 showed a greater FAO rate than untreated ones (Fig. S5A). In agreement, 12 hour TGFβ1 treatment increased the OCR and the expression of fibrotic markers, and these effects were blocked by etomoxir (Fig. S5B-C). Consistent with the activation of LX-2 cells, TGFβ1 also reduced intracellular lipid content, while increasing the levels of ATP and of mitochondrial reactive oxygen species (ROS), as measured by MitoSOX; treatment with etomoxir also

blocked these TGFβ1-induced actions (Fig. S5D-F). In the conditions studied, no differences were detected between LX-2 cells treated with TGFβ1 and those treated with TGFβ1 and etomoxir with respect to protein levels of cleaved caspase-3 or -7, beta-galactosidase staining or mRNA expression levels of *P16* (Fig. S5G-H). We therefore concluded that the inhibitory actions of etomoxir on HSC activation occurred independently of apoptosis and senescence.

Similar to the pharmacological inhibition of CPT1 for 12 hours, the genetic repression of CPT1A in LX-2 cells (Fig. S6A) blocked the increased OCR, reduced lipid content, and increased levels of ATP and ROS provoked by 12 hours of TGFβ1 treatment in the wild-type (WT) cells (Fig. S6B-F), and these features were not related to senescence (Fig. S6G). The results obtained after the activation of LX-2 cells by 12 hour TGFβ1 treatment, and the blockade of those effects after the genetic or pharmacological




Fig. 4. Beta oxidation mediates the activation of HSC LX-2 cells induced by FBS. (A) Fatty acid oxidation rate in LX-2 cells treated with FBS 10% (n = 6), and expression of *CPT1A* in LX-2 cells treated with 10% FBS or 10% lipid-depleted FBS for 1 h (n = 5 or 6). (B) Expression of *αSMA*, *COL1a1*, and *COL1a2* in LX-2 cells treated for 1, 2 and 12 h with 10% FBS or 10% lipid-depleted FBS in presence of etomoxir or vehicle (n = 3–6). (C) Expression of beta oxidation markers in LX-2 cells (n = 5–6). (D) Representative microphotographs of ORO staining in LX-2 cells. Lipids (red area) were quantified and normalized to the total number of nuclei per field (n = 5–6). (E) OCR in LX-2 cells treated with 10 % FBS; 10% FBS and etomoxir; or 10% lipid-depleted FBS (n = 3). mRNA levels were normalized to the housekeeping gene *HPRT*. Data are mean ± SEM. **p* <0.05, ***p* <0.01, ****p* <0.001 according to a Student's *t* test (A) (E) or one-way ANOVA followed by Bonferroni post hoc multiple comparison test (A) (B) (C) (D). FBS, fetal bovine serum; HSC, hepatic stellate cell; OCR, oxygen consumption rate; ORO, oil red O.

inhibition of CPT1A, were consistently maintained at longer periods of time. Specifically, after 48 hours, etomoxir was still able to partially block the higher OCR, lower lipid content, and increased levels of ATP and ROS induced by TGFβ1 treatment (Fig. S7).

To find out whether CPT1A could affect proliferation over long periods of time, we performed EdU assays in LX-2 cells manipulating CPT1A or administering fetal bovine serum (FBS) for 72

hours. The overexpression of CPT1A significantly increased the proportion of EdU-stained cells (Fig. S8A). In addition, incubation of LX-2 cells with 10% FBS, which promotes CPT1A expression (Fig. 4A), increased the proliferation of LX-2 cells (Fig. S8B). On the contrary, the administration of 10% lipid-depleted FBS, a condition that does not increase CPT1A expression (Fig. 4A), was unable to induce cell proliferation (Fig. S6B). Finally, we performed an EdU assay in LX-2 cells downregulating CPT1A with




Fig. 5. The genetic overexpression of CPT1A activates human HSC LX-2 cells and increases the metabolic activation induced by TGFβ1. (A) Expression of CPT1A in LX-2 cells transfected with either 1 ng or 10 ng of plasmid encoding CPT1A (n = 4). (B) OCR and ECAR. Arrows indicate the timepoint at which mitochondrial respiration modulators (Oligo, FCCP, or Rot/AA) were added to the assay. Right, graph depicting the effect of the upregulation of CPT1A on quiescent or energetic metabolic states based on quantification of glycolysis and OCR during basal metabolism. (C) Parameters of mitochondrial function (n = 5-8). (D) Expression of fibrotic markers (n = 4). (E) OCR, ECAR, and basal metabolism in LX-2 cells overexpressing CPT1A following the administration of TGFβ1 for 12 h (n = 6). (F) Parameters of mitochondrial function (n = 3). (G) Expression of fibrotic markers (n = 5). mRNA levels were normalized to the housekeeping gene HPRT. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 according to a Student's t test (F) (G) or one-way ANOVA followed by Bonferroni post hoc multiple comparison test (A) (C) (D). ECAR, extracellular acidification rate; FCCP, phenylhydrazine; HSC, hepatic stellate cell; OCR, oxygen consumption rate; Oligo, oligomycin; Rot/AA, rotenone/antimycin A.

small-interfering RNAs. After 72 hours, we found a slight but non-significant reduction ($p = 0.07$) in the proliferation of LX-2 cells (Fig. S8C). Thus, there is a long-term increase in proliferation of HSCs following the activation of CPT1A, and a tendency to decrease cell proliferation after downregulating CPT1A.

When isolated HSCs are grown in culture with DMEM supplemented with 10% FBS, they spontaneously acquire an active profibrogenic phenotype.^{20–23} Using this experimental paradigm to measure FAO and CPT1A expression, we found that both aspects increased in LX-2 cells incubated with 10% FBS compared to cells incubated in a control medium with 2% FBS (Fig. 4A). Further, LX-2 cells incubated with 10% FBS displayed a time-dependent increase in the expression of the profibrogenic markers α SMA, COL1 α 1, and COL1 α 2 (Fig. 4B). However, if lipids were removed (using a 10% lipid-depleted FBS), the fibrogenic response to the 10% FBS was almost completely blunted (Fig. 4B). Treating the LX-2 cells with etomoxir gave a similar attenuated fibrogenic effect when added to 10% FBS-treated cells (Fig. 4B). Consistent with these results, the expression levels of SCAD (short-chain acyl-CoA dehydrogenase), MCAD (medium-chain acyl-CoA dehydrogenase), or LCAD (long-chain acyl-CoA dehydrogenase) increased in cells incubated with 10% FBS and decreased with 10% lipid-depleted FBS (Fig. 4C). Also, the reduced lipid content and higher OCR associated with 10% FBS-induced activation were blocked after removing lipids from the medium or after etomoxir treatment (Fig. 4D–E). Altogether, these data indicated that HSCs require lipid availability and a functional FAO pathway to be activated.

Overexpression of CPT1A induces *in vitro* HSC activation in an ATP-dependent manner

After demonstrating that inhibition of CPT1A was sufficient to prevent HSC activation, we next performed a gain-of-function experiment by overexpressing CPT1A in LX-2 cells with 2 different doses of plasmid CPT1A (1 and 10 ng) (Fig. 5A) to investigate whether this gene could activate HSCs. Our results showed that the ectopic plasmid expression of CPT1A at both doses stimulated OCR and the expression of fibrotic markers (Fig. 5B–D). Thus, abnormally high levels of CPT1A are enough to activate HSCs. Moreover, overexpressing CPT1A in LX-2 cells previously treated with TGF β 1 led to an enhanced increase of OCR and expression of fibrotic markers (Fig. 5E–G), indicating that CPT1A overexpression may have a summatory effect to TGF β 1 in the activation of HSCs.

To determine whether ATP availability plays a direct role in mediating the effects of FAO activation on fibrogenic activity, we first performed a dose-response analysis with the ATP synthase/Complex-V inhibitor named oligomycin in LX-2 cells overexpressing CPT1A. Oligomycin inhibited CPT1A-induced OCR in a dose-dependent manner, with a complete suppression of OCR at concentrations above 2,000 nM (Fig. S9A). The dose of oligomycin which reduced the CPT1A-induced OCR to similar levels to the control baseline was 330 nM. This means that with this dose of oligomycin, the overexpression of CPT1A could not stimulate OCR but could only maintain mitochondrial respiration at the same extent as in quiescent HSCs. Next, we measured intracellular ATP levels in LX-2 cells under 3 different treatments: controls, overexpression of CPT1A and CPT1A + oligomycin (330 nM). Our results indicated that the overexpression of CPT1A increased intracellular ATP levels, while the cotreatment with oligomycin blunted CPT1A-induced ATP and kept it at baseline

levels (Fig. S9B). Finally, we directly measured the mRNA levels of different fibrogenic markers. Whereas expression of α SMA, COL1 α 1 and COL1 α 2 was upregulated following the overexpression of CPT1A, this increase was almost completely suppressed in LX-2 cells overexpressing CPT1A and treated with oligomycin (Fig. S9C). Thus, our data point to mitochondrial ATP production as a major mediator of the effects of CPT1A overexpression on HSC activation.

Production of ROS by hepatocytes activates HSC

We next aimed to study if ROS, generated by an exacerbated FAO of hepatocytes in the fibrotic liver, could affect HSC activation. To induce ROS, we forced FAO in human HepG2 hepatocytes by: i) overexpression of CPT1A; ii) overload of oleic acid; and iii) both overexpression of CPT1A and treatment with oleic acid. Indeed, the 3 groups showed an elevated expression of CPT1A, the combination of oleic acid and overexpression of CPT1A being the most effective (Fig. S10A). After 12 hours, culture media was replaced by fresh growth media to avoid a potential direct effect of oleic acid in stellate cells. Twelve hours later, culture media were collected and ROS levels were determined. As expected, ROS levels were increased in culture media of FAO-induced hepatocytes in the 3 scenarios (Fig. S10B). Then, we used this conditioned media from hepatocytes to treat human LX-2 cells and, after 30 hours, we analyzed their activation status. The expression of fibrogenic markers α SMA, COL1 α 1 and COL1 α 2 was induced in LX-2 cells receiving the culture medium from hepatocytes overexpressing CPT1A, oleic acid, and the combination of overexpression of CPT1A plus oleic acid (Fig. S10C). Therefore, our results indicate that the induction of FAO in hepatocytes stimulates the generation of ROS, which subsequently induce the activation of HSCs.

To assess the causal role of hepatocyte-generated ROS in the activation of HSCs, we prevented ROS production with N-acetylcysteine (NAC), a well-known antioxidant and precursor of glutathione,²⁴ in FAO-stimulated hepatocytes. As expected, we found that NAC strongly inhibited the ROS production in culture media (Fig. S10B). However, the culture media of NAC-treated cells was partially able to blunt the activation of HSCs (Fig. S10C). This indicates that the profibrogenic effect of FAO-induced hepatocytes on HSCs could be partially mediated by ROS production.

We also assessed the role of ROS within HSCs. For this, we ectopically expressed CPT1A in LX-2 cells and then treated them with either vehicle or NAC.²⁴ As expected, the overexpression of CPT1A increased the levels of ROS, measured as MitoSOX staining area, whereas the administration of NAC in these cells abolished CPT1A-induced ROS production after 24 hours (Fig. S11A). However, the suppression of ROS in LX-2 cells had a minor impact on pCPT1A-induced fibrogenesis, with a (non-significant) reduction of approximately 20% in the expression of fibrogenic markers (Fig. S11B). Overall, these results indicate that, *in vitro*, FAO-derived ROS within HSCs plays a quantitatively less relevant role than exogenous (from hepatocytes) ROS.

Saturated fatty acids are induced by TGF β 1 and induce HSC activation via CPT1A

We next investigated the signaling pathway linking TGF β 1 with CPT1A gene regulation. It has been reported that PPAR α and PPAR γ coactivator (PGC-1 α) are able to induce CPT1A in certain contexts.^{25,26} Therefore, we measured the expression of both genes in LX-2 cells treated with TGF β 1 but failed to detect

significant changes (Fig. S12A). In addition, it has also been shown that long-chain fatty acids regulate liver CPT1 expression through a PPAR α -independent pathway.²⁷ Thus, we investigated the potential role of different fatty acids. First, we performed lipidomics analysis in LX-2 cells treated with TGF β 1 and found an increase in total fatty acids following the administration of TGF β 1 (Fig. 6A). As depicted in the first heatmap, saturated fatty acids, and to a much lesser extent mono- and polyunsaturated fatty acids, contributed to the observed increase. Next, we measured the levels of specific species of saturated fatty acids, and found that 14:0, 15:0, 16:0 and 18:0 fatty acids were increased in LX-2 cells treated with TGF β 1, as represented in the second heatmap (Fig. 6B). The quantification of these lipid species in the TGF β 1+etomoxir group allowed us to detect a further accumulation of species 14:0, 15:0, 16:0 and 17:0, but not 18:0, compared to the cells treated with TGF β 1 alone (Fig. 6B). This agrees with the hypothesis that species 14:0, 15:0, 16:0 and 17:0 are being used to fuel beta oxidation in response to TGF β 1 administration.

Finally, to evaluate if these fatty acids could be able to trigger the activation of HSCs, we performed a functional experiment administering palmitic acid (16:0) at different doses to LX-2 cells. Palmitic acid significantly upregulated CPT1A expression as well as the levels of fibrogenic markers (Fig. 6C). Next, we treated LX-2 cells with palmitic and also silenced CPT1A. While this fatty

acid increased the expression of fibrogenic markers, this effect was blocked when CPT1A was inhibited (Fig. 6D). Conversely, the administration of unsaturated fatty acids such as oleic and linoleic acid did not alter CPT1A expression, nor fibrogenic markers (Fig. S12B). These results indicate that i) TGF β 1 increases the levels of total fatty acids and specially saturated species, which are fueling beta oxidation of activated HSCs, and ii) palmitic acid but not unsaturated fatty acids, such as oleic or linoleic acids, is able to induce a fibrogenic response via CPT1A.

Inhibition of CPT1A in HSCs protects against fibrosis

After showing that CPT1A is increased in patients and animal models of NASH with fibrosis, and that the manipulation of CPT1A plays a critical role in HSC activation *in vitro*, we next aimed to understand the *in vivo* functional relevance of our findings. For this, we crossed *Cpt1a*-floxed mice with bacterial artificial chromosome transgenic mice in which Cre expression is driven by lecithin-retinol acyltransferase,²⁸ to generate mice with a *Cpt1a* knockout (KO) specifically in HSCs (HSC-*Cpt1a*-KO) (Fig. 7A). After feeding mice a MCDD for 6 weeks, CPT1A was clearly colocalized with α SMA in WT mice but not in HSC-*Cpt1a*-KO mice, confirming the efficiency of the recombination (Fig. 7A, Fig. S13). As expected, MCDD caused a significant induction in circulating levels of markers of liver damage, increased collagen deposition and hydroxyproline levels in the liver, and increased




Fig. 6. Increased levels of palmitic acid induce CPT1A and the fibrogenic response in LX-2 cells. (A) Lipidomics analysis of different classes of fatty acids in human LX-2 HSCs treated with TGF β 1 or vehicle for 12 hours (n = 5). (B) Levels of specific species of saturated fatty acids in LX-2 activated by TGF β 1 and following the administration of etomoxir (n = 5). (C) Expression of CPT1A and fibrogenic (α SMA, COL1 α 1, COL1 α 2) markers in LX-2 cells incubated with palmitic acid at doses of 1 μ M and 10 μ M for 4 hours (n = 4). (D) Expression of CPT1A and fibrogenic markers in LX-2 cells after silencing of CPT1A and incubation with 10 μ M palmitic acid for 4 hours (n = 4). mRNA levels were normalized to the housekeeping gene HPRT. Data are mean \pm SEM. **p* < 0.05, ***p* < 0.01, ****p* < 0.001 according to a one-way ANOVA followed by Bonferroni post hoc multiple comparison test. HSC, hepatic stellate cell; si, small-interfering RNA.




Fig. 7. CPT1A deficiency in HSCs protects against liver fibrosis in mice fed a MCDD. HSC-*Cpt1a*-KO or WT mice were fed a SD or a MCDD diet for 6 weeks (n = 4-7). (A) Representative colocalized immunofluorescence for α SMA (red) with CPT1A (green). Nuclei were stained with DAPI (blue). (B) Serum levels of AST and ALT. (C) Liver sections stained with H&E (top), ORO (middle), or Sirius red (bottom); stained areas were quantified. (D) Hepatic hydroxyproline levels. (E) Expression of fibrotic (α SMA, COL1 α 1, COL1 α 2, TGF β) and inflammatory (F4/80, TNF α , and IL1 β) markers in liver. (F) F4/80 immunohistochemistry staining. Stained areas were quantified. mRNA levels were normalized to the housekeeping gene HPRT. Data are mean \pm SEM. **p* < 0.05, ***p* < 0.01, ****p* < 0.001 according to a one-way ANOVA followed by Bonferroni post hoc multiple comparison test. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HSC, hepatic stellate cell; IHC, immunohistochemistry; KO, knockout; MCDD, methionine-choline-deficient diet; ORO, oil red O; SD, standard diet; WT, wild-type.

expression of fibrotic markers (Fig. 7B-E). Importantly, all these MCDD-induced effects were ameliorated in HSC-*Cpt1a*-KO mice (Fig. 7B-E). In addition, the expression levels of inflammatory genes, including F4/80, TNF α , and IL1 β , were upregulated by

MCDD in WT mice but not significantly or to a lower degree in HSC-*Cpt1a*-KO mice (Fig. 7E); this agrees with the decreased amount of inflammatory infiltrates measured by F4/80 staining (Fig. 7F).

In a second model of fibrosis, we injected carbon tetrachloride for 6 weeks into both WT and HSC-*Cpt1a*-KO mice. In WT mice, and as expected, carbon tetrachloride increased the serum levels of transaminases, hepatic collagen deposition, hydroxyproline levels, expression of fibrotic and inflammatory markers, and inflammatory infiltrates (Fig. S14A-F). However, all carbon tetrachloride-induced effects were clearly attenuated in HSC-*Cpt1a*-KO mice (Fig. S14A-E). Likewise, expression analysis in isolated HSCs from HSC-*Cpt1a*-KO mice revealed that fibrogenic activation following carbon tetrachloride treatment was also clearly attenuated (Fig. S14F).

We next used a third model of fibrosis that resembles the characteristic whole-body metabolic deregulation of NASH using a feeding regime of CDHFD vs. SD for HSC-*Cpt1a*-KO

mice. At 10 weeks, both HSC-*Cpt1a*-KO and WT mice fed a CDHFD equally increased their body weight compared to those fed a SD, without changes in food intake (Fig. 8A). Notably, however, the expected increases in serum transaminase levels, hepatic collagen deposition, and hydroxyproline levels, and upregulation of fibrotic and inflammatory markers that were induced by CDHFD in WT mice were significantly attenuated in HSC-*Cpt1a*-KO mice (Fig. 8B-D). Overall, these results indicate that the lack of CPT1A in HSCs protects against fibrosis development.

Discussion

We show here that CPT1A is upregulated in HSCs of patients with fibrosis and animal models of fibrosis, and that CPT1A induces




Fig. 8. CPT1A deficiency in HSCs protects against fibrosis induced by CDHFD in mice. HSC-*Cpt1a*-KO or WT mice were fed a CDHFD or a SD for 10 weeks (n = 6 or 7). (A) Cumulative body weight gain and food intake. (B) Serum levels of AST and ALT. (C) Liver sections stained with H&E (top), ORO (middle), or Sirius red (bottom). Staining areas were quantified. (D) Hepatic hydroxyproline levels. (E) Expression of fibrotic and inflammatory markers in the liver. mRNA levels were normalized to the housekeeping gene HPRT. Data are mean ± SEM. **p* < 0.05, ***p* < 0.01, ****p* < 0.001 according to a one-way ANOVA followed by Bonferroni post hoc multiple comparison test. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CDHFD, choline-deficient and high-fat diet; HSC, hepatic stellate cell; KO, knockout; ORO, oil red O; SD, standard diet; WT, wild-type.

the activation of these cells, thereby contributing to the progression of liver fibrosis. Further, pharmacological and genetic inhibition of CPT1A ameliorates fibrosis by preventing the activation of HSCs. Notably, mice genetically lacking CPT1A in HSCs are protected against fibrosis.

HSC activation depends on the metabolic activation of glycolysis,¹⁰ glutaminolysis,¹¹ and *de novo* lipogenesis.¹² An important number of the current drugs to treat NASH aim to inhibit *de novo* lipogenesis. For instance, inhibition of acetyl CoA carboxylase (ACC), the enzyme that catalyzes the rate-limiting step of *de novo* lipogenesis by converting acetyl co-enzyme A to malonyl-CoA, suppresses the activation of HSCs.¹² Clinical trials have shown that inhibitors of ACC^{29,30} or fatty acid synthase³¹ are efficient at reducing hepatic fat content, fibrosis markers, and liver stiffness in patients with NASH. However, the potential role of FAO in HSCs has remained largely unexplored. This is of importance, given the coordinate regulation of fatty acid metabolism with malonyl-CoA, a main intermediate of fatty acid synthesis, which is the main allosteric inhibitor of CPT1A and therefore FAO.³² In hepatocytes, increased glucose metabolism raises levels of malonyl-CoA, which is a potent allosteric inhibitor of CPT1 and blocks FAO, thereby favoring lipid storage. For this reason, some preclinical studies have aimed to promote FAO to reduce NAFLD.^{14,15,33} However, in response to hepatic injury, HSCs are completely different to hepatocytes. When they are activated, HSCs convert from inactive, vitamin A-rich cells into myofibroblast-like cells with proliferative, migratory, and fibrogenic properties.^{1,34} These features are somewhat similar to the ones displayed by cancer cells, for which it is well established that fatty acids sustain their rapid proliferative rate and provide an essential energy source.^{35,36} Our results showing that CPT1A is overexpressed in HSCs in patients with fibrosis and fibrosis animal models, and that FAO is increased in activated HSCs, are in agreement with the hypothesis that activated HSCs lose their intracellular lipid droplets to provide fatty acids for activation and transdifferentiation. These results are functionally corroborated by genetic overexpression of CPT1A, which is not only sufficient to activate HSCs *per se* but also enhances TGF β -induced fibrosis. In line with the cell-specific effects that CPT1 may play, intrahepatic CD4+ T cells or mice exposed to linoleic acid show elevated levels of CPT, while the pharmacological blockade of CPT decreases apoptosis of intrahepatic CD4+ T cells and inhibits HCC tumor formation.³⁷ These results highlight that each cell type has a specific metabolic rewiring in response to injury, and that activating CPT1A does not always exert a beneficial action in the liver.

A descriptive study has previously shown that the expression of PPAR β is increased in activated primary HSCs.⁶ Activation of PPAR β was initially related to its adipogenic role, but this gene is also known to induce FAO,³⁸ even though its capacity to regulate HSC activation via FAO has not been tested. To our knowledge, our study is the first to demonstrate that CPT1A is consistently elevated in both LX-2 cells and pHSCs activated by different stimuli, as well as in animal models and patients with NASH. Moreover, we also show that CPT1A is functionally relevant, as both genetic and pharmacological inhibition of CPT1A ameliorated fibrosis *in vitro* and *in vivo*. In line with this, one report indicated that the mouse stellate JS1 cell line treated with etomoxir induces lipid droplet accumulation in these cells and reduces the expression of fibrotic markers.²³ However, this result was obtained by using etomoxir at a relatively high dose (20 μ M;

note that we used 4 μ M for our experiments). This is a relevant fact, as high doses of etomoxir are known to promote FAO independently of CPT1A and to exert off-target effects,^{39,40} so it is difficult to draw a solid conclusion concerning the role of CPT1A from a single experiment using this inhibitor. It is also necessary to take into consideration that, in some cell types, oxidative metabolism induced by etomoxir at concentrations exceeding 5 μ M is independent of its effects on FAO, and that concentrations induce acute production of ROS with associated evidence of severe oxidative stress.⁴¹ Our experiments with etomoxir at a dose of 4 μ M showed a clear amelioration of HSC activation by different stimuli. Importantly, this beneficial action was not associated with changes in ROS levels. We also failed to detect any alteration in proton leaks in our OCR analysis, indicating that etomoxir did not damage the mitochondrial membrane. Critically, all of our findings obtained from the pharmacological inhibition of CPT1A with etomoxir were reproduced by genetic silencing.

The mechanism activating CPT1A involved saturated long-chain fatty acids, such as palmitic acid, which induces HSC activation in a CPT1A-dependent manner, while unsaturated fatty acids failed to exert such effects. This is in agreement with a previous study showing that long-chain fatty acids can directly regulate liver CPT1 expression.²⁷ CPT1A-induced fibrogenesis is highly dependent of ATP availability since the inhibition of ATP synthase blunted the upregulation of fibrogenic markers upon the ectopic expression of CPT1A in HSCs. However, the role of ROS generated within HSC seems to be less relevant for the actions of CPT1A.

The causal effects of *in vitro* CPT1A inhibition were corroborated in mice specifically lacking CPT1A in HSCs. These mice were subjected to 3 different fibrosis-inducing conditions: MCDD, carbon tetrachloride, and CDHFD. In all cases, CPT1A deficiency in HSCs protected the animals against fibrosis and inflammation. Importantly, our results indicate that CPT1A-induced effects were not due to effects on cell death or senescence.

These results support the hypothesis that activated HSCs display an enhanced metabolism that accommodates their accelerated biological functions and increased energy requirements. FAO and mitochondrial activity seem to play a key role in generating an energy source for activation and proliferation of HSCs; in turn, when CPT1A is inhibited, HSCs exhibit a more inactive phenotype with suppressed metabolism. Altogether, these findings indicate that compounds specifically targeting CPT1A in HSCs may open a new avenue for the treatment of liver fibrosis.

Abbreviations

α SMA, α -smooth muscle actin; ACC, acetyl CoA carboxylase; CDHFD, choline-deficient and high-fat diet; COL1A1 or COL1A2, collagen alpha 1/2; CPT, carnitine palmitoyltransferase; ECAR, extracellular acidification rate; FAO, fatty acid oxidation; FBS, fetal bovine serum; GFAP, glial fibrillary acidic protein; HFD, high-fat diet; HSCs, hepatic stellate cells; KO, knockout; MCDD, methionine-choline-deficient diet; NAC, N-acetyl-cysteine; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OCR, oxygen consumption rate; pHSCs, primary human HSCs; PPAR, peroxisome proliferator-activated

receptor; ROS, reactive oxygen species; SD, standard diet; TGFβ1, transforming growth factor-β1; WT, wild-type.

Financial support

This work has been supported by grants from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (DS and LH: SAF2017-83813-C3-1-R; MLMC: RTC2019-007125-1; CD: BFU2017-87721; ML: RTI2018-101840-B-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; MLMC: SAF2017-87301-R; TCD: RTI2018-096759-A-100), Xunta de Galicia (ML: 2016-PG068; RN: 2015-CP080 and 2016-PG057), Fundación BBVA (RN and MLM), Proyectos Investigación en Salud (MLMC: DTS20/00138), Sistema Universitario Vasco (PA: IT971-16); Fundación Araucaria (ML and RN), Gilead Sciences International Research Scholars Program in Liver Disease (MVR), Marató TV3 Foundation (DS: 201627), Government of Catalonia (DS: 2017SGR278) and European Foundation for the Study of Diabetes (RN). This research also received funding from the European Community's H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to RN, VP and MS). Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd). CIBERobn and CIBERehd are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644).

Conflict of interest

The authors declare that they have no conflicts of interest related to the study.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

M.F.F., U.F., V.H., A.A.F., T.P., M.J.G.-R., E.N., B.P., C.A., R.M., N.D.S.L., C.I., A.S., T.C.D., A.W., L.H., D.S., M. V-R., P.I.: study conception and design, data acquisition, and data analysis and interpretation; M.F.F., V.P., M.S., O.M., J.M.M., M.L., C.D., F.J.C., P.I., J.C., M.L.M.-C., R. F.S., R.N.: manuscript writing and final review.

Data availability statement

The data associated with this paper are available upon request to the corresponding author.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2022.02.003>.

References

Author names in bold designate shared co-first authorship

- [1] Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. *Physiol Rev* 2008;88:125–172.
- [2] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. *Nat Rev Gastroenterol Hepatol* 2021;18:151–166.
- [3] Tacke F, Trautwein C. Mechanisms of liver fibrosis resolution. *J Hepatol* 2015;63:1038–1039.
- [4] Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. *Gastroenterology* 2020;158:1913–1928.
- [5] **Lomba R, Friedman SL, Shulman GI.** Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell* 2021;184:2537–2564.

- [6] She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. *J Biol Chem* 2005;280:4959–4967.
- [7] Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. *J Gastroenterol Hepatol* 2006;21(Suppl 3):S102–105.
- [8] **Wang JN, Li L, Li LY, Yan Q,** Li J, Xu T. Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis. *Gene* 2018;674:57–69.
- [9] Trivedi P, Wang S, Friedman SL. The power of plasticity-metabolic regulation of hepatic stellate cells. *Cell Metab* 2021;33:242–257.
- [10] Chen Y, Choi SS, Michelotti GA, Chan IS, Swiderska-Syn M, Karaca GF, et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism. *Gastroenterology* 2012;143:1319–1329.e1311.
- [11] Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, Swiderska-Syn M, et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. *Gastroenterology* 2018;154:1465–1479.e1413.
- [12] Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyevev D, et al. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. *J Hepatol* 2020;73:896–905.
- [13] Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula JJ, Brown NF, O'Doherty RM. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. *Am J Physiol Endocrinol Metab* 2008;294:E969–977.
- [14] Orellana-Gavalda JM, Herrero L, Malandrino MI, Paneda A, Sol Rodriguez-Pena M, Petry H, et al. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. *Hepatology* 2011;53:821–832.
- [15] Weber M, Mera P, Casas J, Salvador J, Rodríguez A, Alonso S, et al. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. *Faseb j* 2020;34:11816–11837.
- [16] Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005;41:1313–1321.
- [17] Uyama N, Zhao L, Van Rossen E, Hirako Y, Reynaert H, Adams DH, et al. Hepatic stellate cells express synemin, a protein bridging intermediate filaments to focal adhesions. *Gut* 2006;55:1276–1289.
- [18] Scholten D, Osterreicher CH, Scholten A, Iwaisako K, Gu G, Brenner DA, et al. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. *Gastroenterology* 2010;139:987–998.
- [19] Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. *Gut* 2005;54:142–151.
- [20] de Oliveira da Silva B, Alberici LC, Ramos LF, Silva CM, da Silveira MB, Dechant CRP, et al. Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism. *Int J Biochem Cell Biol* 2018;98:137–155.
- [21] Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. *J Submicrosc Cytol Pathol* 1992;24:193–203.
- [22] Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, et al. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. *Hepatology* 2008;48:963–977.
- [23] Hernandez-Gea V, Friedman SL. Autophagy fuels tissue fibrogenesis. *Autophagy* 2012;8:849–850.
- [24] Wang F, Liu S, Shen Y, Zhuang R, Xi J, Fang H, et al. Protective effects of N-acetylcysteine on cisplatin-induced oxidative stress and DNA damage in HepG2 cells. *Exp Ther Med* 2014;8:1939–1945.
- [25] Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, et al. Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. *Mol Cell Endocrinol* 2010;325:54–63.
- [26] Louet JF, Hayhurst G, Gonzalez FJ, Girard J, Decaux JF. The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB). *J Biol Chem* 2002;277:37991–38000.
- [27] **Louet JF, Chatalein F,** Decaux JF, Park EA, Kohl C, Pineau T, et al. Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. *Biochem J* 2001;354:189–197.

- [28] Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nat Commun* 2013;4:2823.
- [29] Lawitz EJ, Coste A, Poordad F, Alkhoury N, Loo N, McColgan BJ, et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 Weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2018;16:1983–1991.e1983.
- [30] Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. *Gastroenterology* 2018;155:1463–1473.e1466.
- [31] Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, et al. TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. *Gastroenterology* 2021.
- [32] Schlaepfer IR, Joshi M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential. *Endocrinology* 2020;161.
- [33] Monsenego J, Mansouri A, Akkaoui M, Lenoir V, Esnous C, Fauveau V, et al. Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis. *J Hepatol* 2012;56:632–639.
- [34] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. *Nat Rev Gastroenterol Hepatol* 2017;14:397–411.
- [35] Koundouros N, Pouligiannis G. Reprogramming of fatty acid metabolism in cancer. *Br J Cancer* 2020;122:4–22.
- [36] Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. *Nat Rev Cancer* 2013;13:227–232.
- [37] Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4(+) T cell apoptosis promoting HCC development. *Cell Death Dis* 2018;9:620.
- [38] Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. *Trends Endocrinol Metab* 2012;23:351–363.
- [39] **Raud B, Roy DG**, Divakaruni AS, Tarasenko TN, Franke R, Ma EH, et al. Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation. *Cell Metab* 2018;28:504–515.e507.
- [40] Yao CH, Liu GY, Wang R, Moon SH, Gross RW, Patti GJ. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of beta-oxidation. *Plos Biol* 2018;16:e2003782.
- [41] O'Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. *Sci Rep* 2018;8:6289.